In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.
- Nanotechnology Drug Delivery: A Market Overview
- Combination: The Drug Delivery Word Of The Year For 2026
- In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors
- Electronic Drug Delivery Devices Market: Advancing Smart, Connected Healthcare
- Regulating For Patient Safety And Success With Combination Products
- FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs
- Strained Manufacturing, Complexity Stymie In Vivo Progress
- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Compliance Considerations For Emergency-Use Delivery Systems
Because auto-injectors are typically the delivery device of choice for emergency medications, they come with increased scrutiny from regulatory bodies regarding their safety and effectiveness.
-
Small-Scale Aseptic Filling Technology Considerations
Small-scale aseptic filling presents a unique set of challenges. Learn what to look for when evaluating small-scale aseptic filling technology.
-
Pediatric Dosage Form Development: Program Design And Formulation Development
Explore key considerations to successfully bridge from initial concept of pediatric program design and formulation development strategies into later stages of development and through to commercialization.
-
Nanosuspension Dosage Forms: Product Development & Scale Up
For drug nanosuspensions, parameters like stabilizer concentration, drug loading, milling speed, milling time, bead diameter/density, and temperature are important formulation and process variables.
-
Sterile Injectable Therapies: Revolutionizing Lifecycle Management
The right balance of technical understanding, logistics, regulatory guidelines, and knowledge about product stability and quality is crucial for capitalizing on the benefits of shifting delivery formats.
-
From Regulators To PUPSIT: Notes On Annex 1 Revision Implementation
Kevin Smyth, a biochemical engineer with 30 years of experience in the pharmaceutical industry, offers insights and expertise in working with firms to understand what regulators seek to meet new standards.
-
How Devices, Instructions, And Packaging Work Together To Improve Safety
A medical device's user interface is the entire product system: the device, labeling, packaging, and IFU. These elements are crucial for risk mitigation and must be tested holistically.
-
How To Achieve Precise And Flexible Dosing With Multiparticulates
For orally delivered medicines, developers often must balance a drug’s “curb appeal” — its specific delivery mechanism, taste, ease of administration, and convenience — with safety and efficacy.
-
Ophthalmic Formulation Development: Inside Ophthalmic Preparation
Understand why the demand for CDMOs with experience in the formulation of ophthalmic products is on the rise.
-
Opioid Reformulation Filed As A CMC Supplement In Less Than A Year
Some reformulation projects are more challenging than others. See how innovative processing equipment from Freund-Vector was leveraged to develop an efficient and effective solution.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026
In this article, Fran DeGrazio identifies four notable trends in drug delivery that gained momentum in 2025 and, she predicts, will continue to do so in 2026 and beyond. They are digitalization, sustainability, patient centricity, and the advanced delivery of complex biopharmaceuticals.

